Key result
A meds-to-beds discharge program is not linked to fewer 30-day readmissions versus no program.
Why the study?
Effective transitional care programs from hospital to home are needed to improve patient outcomes.
Does a "meds-to-beds" program reduce 30-day readmissions in hospitalized patients?
Population
500 intervention and 1591 control hospitalized patients eligible for the meds-to-beds program
Comparison
Opting into the meds-to-beds program vs not opting in
Design
Retrospective, observational cohort study
Follow-up
30 days
Authors
Loading...
Does not support routine meds-to-beds adoption for all-cause readmissions; leaves open possible preventable-readmission benefit requiring confirmation.
Cohort (n=2,091)
Does a "meds-to-beds" program reduce 30-day readmissions in hospitalized patients?
Odds Ratio: 0.67 (95% CI 0.42–1.07)
p-value: p=0.09
A "meds-to-beds" discharge program significantly reduced 30-day preventable hospital readmissions, although it did not significantly reduce all-cause readmissions.
Zillich et al. (2019) conducted a cohort in Hospitalized patients (n=2,091). Meds-to-beds program vs. Eligible patients who did not opt-in was evaluated on any 30-day readmissions (OR 0.67, 95% CI 0.42-1.07, p=0.09). A 'meds-to-beds' discharge program was not associated with a significant reduction in 30-day all-cause readmissions compared to no program (OR 0.67; 95% CI 0.42-1.07; P=0.09).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: